Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exactech to raise $20.2 million from sale of common stock
Exactech has offered the shares pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. The offering is expected to close on or before
Exactech has offered the shares pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. The offering is expected to close on or before
This comes on the heels of the Patent Office’s decision in April, 2008 to allow Vnus a separate patent application, also filed as a continuation of one of
This notice of no objection allows for the initiation of human clinical studies in Canada. The first Phase I clinical trial will assess the safety of PMX-30063. The
Mr Jackson joined Celator in October 2007 as head of commercial development. Mr Jackson has extensive experience in the pharmaceutical and biotechnology industry and has held positions of
Drospirenone and ethinyl estradiol product is a generic version of Yasmin, an oral contraceptive product manufactured and marketed by Bayer Schering Pharma. Yasmin is a 28-day oral contraceptive
Under the terms of the agreement, SomaLogic will receive committed research funding and will be entitled to receive a royalty on any marketed products developed as a result
The Court of Appeal pointed that the National Institute for Health and Clinical Excellence’s (NICE’s) refusal to allow Pfizer and Eisai full access to a computer model used
The final purchase price consisted of approximately $143.9 million, and approximately 1.8 million shares of Inverness series B convertible perpetual preferred stock. In addition, existing options to purchase
Under the terms of the agreement, Invitrogen will have the right to work with karyotypically normal human embryonic stem cells (hESCs) to develop novel research and drug discovery
The orphan drug designation provides eligibility for a seven-year period of market exclusivity in the US after product approval, an accelerated review process, grant funding, tax benefits and